Clinical trial

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

NCT06452433

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention gumarontinib Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-06-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

gumarontinibDRUG

third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)DRUG

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06452433 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.